FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

2014 ◽  
Vol 15 (10) ◽  
pp. 1065-1075 ◽  
Author(s):  
Volker Heinemann ◽  
Ludwig Fischer von Weikersthal ◽  
Thomas Decker ◽  
Alexander Kiani ◽  
Ursula Vehling-Kaiser ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Line Treatment ◽  
First Line ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase ◽  
First Line Treatment

A Phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 3658-3658
Author(s):  
T. H. Cartwright ◽  
T. Lopez ◽  
S. J. Vukelja ◽  
C. Encarnacion ◽  
K. A. Boehm ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Line Treatment ◽  
First Line ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
First Line Treatment

Randomized phase 3 study of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (mCRC): The SALTO study of the Dutch Colorectal Cancer Group.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 3640-3640 ◽  
Author(s):  
Cornelis J. A. Punt ◽  
Lieke H Simkens ◽  
Johan Van Rooijen ◽  
Agnes W Van de Wouw ◽  
Olaf Loosveld ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Line Treatment ◽  
First Line ◽  
Phase 3 ◽  
Cancer Group ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document